Kymera (KYMR) CLO Brian Adams Sells 6,371 Shares

What Happened
Brian Adams, Chief Legal Officer of Kymera Therapeutics (KYMR), sold a total of 6,371 shares on September 4, 2026 for aggregate proceeds of approximately $744,297. The sales were reported as open-market/private dispositions (code S) and broken down as: 1,209 shares at $115.55 ($139,700), 3,025 shares at $116.81 ($353,350), and 2,137 shares at $117.57 (~$251,247). According to the filing, these sales were to satisfy tax-withholding obligations tied to the vesting of restricted stock units and were automatic, not discretionary.

Key Details

• Transaction date: 2026-09-04 (all sales)
• Reported prices and proceeds: 1,209 @ $115.55 ($139,700); 3,025 @ $116.81 ($353,350); 2,137 @ $117.57 (~$251,247). Total ≈ $744,297.
• Footnotes: Sales were required to cover tax withholding on RSU vesting (automatic). Reported per-share prices are weighted averages across multiple trades; ranges cited in the filing span $115.09–$117.85 (details available on request).
• Shares held after the transactions: not specified in the provided filing extract.
• Timeliness: filing shows the transaction and report dated 2026-09-04; no late filing indicated in the provided information.

Context
These were sales to cover tax withholding related to RSU vesting (routine, automatic dispositions) rather than discretionary open-market selling that might signal a view on the stock. For retail investors, such tax-related sales are common and generally not read as a strong signal about insider sentiment.